Integrated analysis of efficacy and safety of palonosetron (PALO) 0.75 mg IV for preventing chemotherapy-induced nausea and vomiting (CINV) in anthracycline and cyclophosphamide (AC/EC) combination chemotherapy in Japan: PALO Japanese breast cancer cooperative study group.

被引：0
|
作者：
Suzuki, Y.
Tokuda, Y.
Inoue, K.
Aogi, K.
Saito, M.
Yanagita, Y.
机构：
[1] Tokai Univ, Sch Med, Kanagawa 2591100, Japan
[2] Saitama Canc Ctr, Saitama, Japan
[3] Natl Hosp Org, Shikoku Canc Ctr, Shikoku, Ehime, Japan
[4] Juntendo Univ, Sch Med, Tokyo 113, Japan
[5] Gunma Canc Ctr, Gunma, Japan
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：280S / 280S
页数：1
相关论文
共 35 条
  • [31] A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide
    Matsumoto, Koji
    Takahashi, Masato
    Sato, Kazuhiko
    Osaki, Akihiko
    Takano, Toshimi
    Naito, Yoichi
    Matsuura, Kazuo
    Aogi, Kenjiro
    Fujiwara, Kimiko
    Tamura, Kenji
    Baba, Motoi
    Tokunaga, Shinya
    Hirano, Gen
    Imoto, Shigeru
    Miyazaki, Chieko
    Yanagihara, Kazuhiro
    Imamura, Chiyo K.
    Chiba, Yasutaka
    Saeki, Toshiaki
    CANCER MEDICINE, 2020, 9 (10): : 3319 - 3327
  • [32] Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies
    Aapro, Matti
    Navari, Rudolph M.
    Roeland, Eric
    Zhang, Li
    Schwartzberg, Lee
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
  • [33] A prospective, randomized, double-blind phase 3 trial of extended-release granisetron (APF530) versus palonosetron (PALO) for preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately (MEC) or highly (HEC) emetogenic chemotherapy: Does a reanalysis using newer ASCO emetogenicity criteria affect study conclusions?
    Raftopoulos, Harry
    Boccia, Ralph V.
    Cooper, William
    O'Boyle, Erin
    Gralla, Richard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study
    Llombart-Cussac, Antonio
    Ramos, Manuel
    Dalmau, Elsa
    Garcia-Saenz, Jose A.
    Gonzalez-Farre, Xavier
    Murillo, Laura
    Calvo, Lourdes
    Morales, Serafin
    Caranana, Vicente
    Gonzalez, Ana
    Fernandez-Morales, Luis A.
    Moreno, Fernando
    Isabel Casas, Ma
    del Mar Angulo, Ma
    Carmen Camara, Ma
    Garcia-Mace, Ana I.
    Carrasco, Eva
    Jara-Sanchez, Carlos
    EUROPEAN JOURNAL OF CANCER, 2016, 58 : 122 - 129
  • [35] Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B)
    Ozeki, Rie
    Iihara, Hirotoshi
    Shimokawa, Mototsugu
    Hashimoto, Hironobu
    Abe, Masakazu
    Mukohara, Toru
    Bando, Hiroko
    Hayashi, Toshinobu
    Kawazoe, Hitoshi
    Komoda, Masayo
    Takahashi, Takako Yanai
    Saito, Mitsue
    BMJ OPEN, 2022, 12 (03): : e058755
1234